The global oncology drugs market size in 2026 is witnessing significant expansion as pharmaceutical companies continue to develop advanced therapies for different types of cancer. Oncology drugs are prescription medicines used to treat various forms of cancer, including solid tumors and hematologic malignancies. Increasing cancer incidence, advances in diagnostic technologies, the growing use of biomarker testing, and the introduction of innovative therapies are supporting the expansion of the market.
According to Fortune Business Insights, the global oncology drugs market size was valued at USD 256.46 billion in 2025. The market is projected to grow from USD 286.36 billion in 2026 to USD 697.59 billion by 2034, exhibiting a CAGR of 11.77% during the forecast period. North America dominated the oncology drugs market with a market share of 45.44% in 2025.
Oncology drugs encompass a broad range of therapeutic products designed to manage different cancers. The market includes cytotoxic drugs, targeted drugs, hormonal drugs, and other drug classes. Treatment approaches covered by the market include chemotherapy, targeted therapy, immunotherapy, and others. The increasing use of targeted medicines and immunotherapy is contributing to changes in cancer treatment pathways. The market is also experiencing a shift toward treatment initiation at earlier stages of cancer. Innovations in diagnostic technologies, including biomarker testing, are helping support treatment decisions. Companion diagnostics, real-world evidence, and payer cost-effectiveness considerations are increasingly influencing oncology drug uptake.
Market Drivers: The increasing prevalence and incidence of cancers such as breast cancer and lung cancer are important factors supporting market growth. Tobacco smoking, higher exposure to ultraviolet radiation, rising pollution levels, and changing diet patterns are identified as factors associated with the increasing cancer burden. In addition, advanced therapies such as antibody-drug conjugates combine the specificity of targeted drugs with the tumor-killing capabilities of cytotoxic medicines, supporting demand for innovative treatments.
The development of strong product pipelines and advanced product launches is another important market growth factor. Pharmaceutical companies are focusing on innovative oncology medicines and expanding their portfolios across different cancer indications.
Market Restraints: Reimbursement pressures can restrict the wider adoption of high-cost cancer drugs. Healthcare payers may require clear evidence of survival or quality-of-life benefits compared with the price of premium medicines. Prior authorization requirements, limited treatment centers, and line-of-therapy restrictions can also affect access to advanced therapies.
Complex manufacturing and supply requirements present additional challenges, particularly for antibody-drug conjugates and radioligand therapies. These treatments can require specialized production processes, sterile fill-finish capabilities, radioisotope handling, and closely coordinated distribution.
The global oncology drugs market features a semi-fragmented competitive landscape with major pharmaceutical companies maintaining broad oncology portfolios and advanced product pipelines. Merck & Co., Inc., AstraZeneca, and Bristol-Myers Squibb Company are among the major players identified in the market.
Companies are pursuing strategic initiatives such as acquisitions, licensing agreements, partnerships, and the development of innovative oncology products to strengthen their market positions. The presence of blockbuster cancer drugs, established geographic reach, and strong oncology pipelines contributes to the competitive positioning of leading pharmaceutical companies.
Hoffmann-La Roche Ltd.
AbbVie Inc.
Novartis AG
Pfizer Inc.
AstraZeneca
GSK plc
Eli Lilly and Company